ABL1 and leukemia: The mechanisms of CML patients resistant to TKIs can be divided into BCR::ABL1-dependent and BCR::ABL1-independent resistance; the former includes BCR::ABL1 mutation and amplification, and the latter includes abnormal energy metabolism and the persistence of leukemia stem cells (Lei et al., 2021) due to bypass activation (Talati and Pinilla-Ibarz 2018).